National Amoxicillin-Clavulanate Formulation Use Pattern: A Survey.

Q2 Medicine

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2023-01-01 Epub Date: 2023-06-02 DOI:10.5863/1551-6776-28.3.192

Gretchen Brummel, Chad A Knoderer

{"title":"National Amoxicillin-Clavulanate Formulation Use Pattern: A Survey.","authors":"Gretchen Brummel, Chad A Knoderer","doi":"10.5863/1551-6776-28.3.192","DOIUrl":null,"url":null,"abstract":"Objective: Five commercially available amoxicillin-clavulanate (AMC) ratio formulations contribute to ratio selection variability with efficacy and toxicity implications. The objective of this survey was to determine AMC formulation use patterns across the United States.Methods: A multicenter practitioner survey was distributed to multiple listservs (American College of Clinical Pharmacy pediatrics, infectious diseases, ambulatory care, pharmacy administration; American Society of Health-System Pharmacists; Pediatric Pharmacy Association members), and selected pediatric Vizient members in June 2019. Responses were screened for multiples within institutions. Repeated organization responses were identified (n = 37) and excluded if the duplicate matched another response from the same organization exactly (n = 0).Results: One hundred ninety independent responses were received. Nearly 62% of respondents represented a children's hospital within an acute care hospital; remainder being from stand-alone children's hospitals. Around 55% of respondents indicated prescribers were responsible for choosing the patient-specific formulation for inpatients. Nearly 70% of respondents indicated multiple formulations were available due to clinical need (efficacy, toxicity, measurable volume), whereas over 40% responded that the number of liquid formulations were limited to decrease the potential for error. Variability was demonstrated among institutions using ≥ 2 different formulations for acute otitis media (AOM), sinusitis, lower respiratory tract infection, skin and soft tissue infection, and urinary tract infection (33.6%, 37.3%, 41.5%, 35.8%, and 35.8%, respectively). The 14:1 formulation was the most common, but not exclusive, for AOM, sinusitis, and lower respiratory tract infections with 2.1%, 2.1%, and 2.6% of respondents indicating use of the 2:1 formulation and 10.9%, 15%, and 16.6% of respondents indicating use of the 4:1 formulation.Conclusions: Significant AMC formulation selection variability exists across the United States.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 3","pages":"192-196"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249967/pdf/i2331-348X-28-3-192.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5863/1551-6776-28.3.192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Five commercially available amoxicillin-clavulanate (AMC) ratio formulations contribute to ratio selection variability with efficacy and toxicity implications. The objective of this survey was to determine AMC formulation use patterns across the United States.

Methods: A multicenter practitioner survey was distributed to multiple listservs (American College of Clinical Pharmacy pediatrics, infectious diseases, ambulatory care, pharmacy administration; American Society of Health-System Pharmacists; Pediatric Pharmacy Association members), and selected pediatric Vizient members in June 2019. Responses were screened for multiples within institutions. Repeated organization responses were identified (n = 37) and excluded if the duplicate matched another response from the same organization exactly (n = 0).

Results: One hundred ninety independent responses were received. Nearly 62% of respondents represented a children's hospital within an acute care hospital; remainder being from stand-alone children's hospitals. Around 55% of respondents indicated prescribers were responsible for choosing the patient-specific formulation for inpatients. Nearly 70% of respondents indicated multiple formulations were available due to clinical need (efficacy, toxicity, measurable volume), whereas over 40% responded that the number of liquid formulations were limited to decrease the potential for error. Variability was demonstrated among institutions using ≥ 2 different formulations for acute otitis media (AOM), sinusitis, lower respiratory tract infection, skin and soft tissue infection, and urinary tract infection (33.6%, 37.3%, 41.5%, 35.8%, and 35.8%, respectively). The 14:1 formulation was the most common, but not exclusive, for AOM, sinusitis, and lower respiratory tract infections with 2.1%, 2.1%, and 2.6% of respondents indicating use of the 2:1 formulation and 10.9%, 15%, and 16.6% of respondents indicating use of the 4:1 formulation.

Conclusions: Significant AMC formulation selection variability exists across the United States.

查看原文本刊更多论文

全国阿莫西林-克拉维酸制剂使用模式：调查。

目的：五种市售阿莫西林-克拉维酸（AMC）配比制剂造成了配比选择的变化，并对疗效和毒性产生了影响。本次调查的目的是确定全美 AMC 制剂的使用模式：方法：2019 年 6 月，向多个列表服务器（美国临床药剂学院儿科、传染病、非住院护理、药剂管理；美国健康系统药剂师协会；儿科药剂协会会员）和选定的儿科 Vizient 会员分发了一份多中心从业人员调查。对机构内的重复回复进行了筛选。确定了重复的机构回复（n = 37），如果重复回复与同一机构的其他回复完全匹配，则排除重复回复（n = 0）：结果：共收到 190 份独立回复。近 62% 的受访者来自急症护理医院中的儿童医院；其余受访者来自独立的儿童医院。约 55% 的受访者表示，处方医生负责为住院患者选择患者专用制剂。近 70% 的受访者表示，由于临床需要（疗效、毒性、可测量的剂量），可提供多种制剂，而超过 40% 的受访者表示，限制液体制剂的数量是为了减少出错的可能性。对于急性中耳炎 (AOM)、鼻窦炎、下呼吸道感染、皮肤和软组织感染以及尿路感染，使用≥ 2 种不同配方的机构之间存在差异（分别为 33.6%、37.3%、41.5%、35.8% 和 35.8%）。14:1配方在治疗AOM、鼻窦炎和下呼吸道感染方面最为常见，但并非唯一，分别有2.1%、2.1%和2.6%的受访者表示使用过2:1配方，10.9%、15%和16.6%的受访者表示使用过4:1配方：美国各地的 AMC 配方选择存在很大差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pediatric Pharmacology and Therapeutics Medicine-Pediatrics, Perinatology and Child Health

CiteScore

2.40

自引率

0.00%

发文量

期刊介绍： The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy. The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues. The Journal will contain original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.